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The use of automatic chest compressions for cardiac arrest began 15 years ago. Since it is available in emergency medicine, it has raised a fascinating debate. This fascination comes from the first animal study in which the use of this device showed a great haemodynamic effect. 1, 2 It was rapidly approved worldwide by the Emergency Medical Systems (EMS) for the quality of the cardiopulmonary resuscitation (CPR) with a reduced EMS team. For the first time, patients could be transported to the hospital while undergoing good quality CPR in safe conditions for the EMS team. For this reason, automated CPR with mechanical chest compressions was generalized in most of the developed EMS. However, in 2014 the negative results of two large randomized studies with the two different major devices available at that time were published: the Autopulse V C (CIRC trial) 3 and the LUCAS V C (LINC trial). 4 These two studies compared survival after CPR using either automatic chest compressions or optimized manual chest compressions. After these results, the value of automatic chest compressions was debated: should we use the devices if there is no increase in survival? Furthermore, these devices are expensive, and can be harmful, as some data suggest that the use of these devices can lead to internal damage. More recently, the last cardiac arrest international guidelines outlined that extracorporeal cardiopulmonary resuscitation (ECPR) or rapid transfer to angiography for CPR should be considered for refractory cardiac arrest. 5 The transfer of a patient undergoing high quality CPR cannot be considered in safe conditions without mechanical devices. Therefore, the safety aspect of the use of mechanical chest compression is a critical issue, for the patient and the team in charge of the patient.
With this in mind, in this issue of the journal, Koster et al. tried to answer this question. 6 In a monocentric randomized study they compared the use of the LUCAS and the Autopulse to optimize manual CPR. The main endpoint was 'serious or lfe-threatening resuscitation-related damage to visceral organs'. The second endpoint was the damage to the chest/ribs. This study can be considered as a safety study. The authors used a smart methodology to evaluate the damage by a combination of computed tomography (CT) autopsy, classical autopsy, and clinical course. In this study, neither of the two devices produced a significant increase of serious or life-threatening resuscitation damage: the main endpoint occurred in 6.4% of patients of the control group, 11.6% for the Autopulse P = 0.15 (compared with the control group), and 7.4% P = 0.75 for the LUCAS group (compared with the control group). For the second endpoint, the results were also negative (P = 0.51 and P = 0.82 compared with the control group for Autopulse and LUCAS, respectively). However, for the authors, 'To accept the non-inferiority hypothesis, the upper bound of the 95% confidence interval of an observed rate difference of damage between mechanical or manual chest compressiontreated patients should not exceed þ10%'. They used this endpoint to power this study. For this reason, they conclude that there is a difference in the results between the two devices used. The LUCAS is non-inferior in terms of safety compared with manual CPR with this criterion, whereas the Autopulse cannot reach the objective of non-inferiority for this safety issue.
This difference can easily be understood by the technique used by these two devices. On the one hand, for the LUCAS device, the objective is to concentrate pressure on the sternum. Surprisingly, with this device, two patients died from liver rupture. The mechanism of this lesion can be attributed to the high pressure transferred to the diaphragm and more probably to mispositioning of the LUCAS device. This calls for better training of the user. In this study, the rescuers were trained every 6 months. On the other hand, the Autopulse increases the pressure in the entire chest, with potentially more organs affected by the increase in pressure, in particular the lungs. This phenomenon explains the more important rate of pneumothorax and pneumomediastianium/oesophagus oedema. In the control group, CPR was delivered by a conventional CPR optimized by retro control of quality in terms of depth and rhythm. However, despite this feedback, depth was not efficient. These results show the difficulty in delivering high quality manual CPR despite the use of modern technology during an interventional study, generally associated with an increase in the quality of CPR. The feedback tools are known to improve the quality, but unfortunately we have no evidence in term of survival. 7 This insufficient depth of manual cardiac massage partially explains the lower rate of damage observed in the control group compared with the 10% expected by the authors when designing the study. One of the major limits for the interpretation of clinical significance of this work is the short delay with which mechanical CPR is used (only 21 or 22 min), after a long period of manual CPR. For instance, in most ECPR programmes, the time with ongoing mechanical chest compression is more likely to be 60 min. 8, 9 Some questions remain unclear concerning the use of the mechanical chest compressions. First of all, what is the ventilation mode associated with this case? Non-synchronous ventilation can be harmful, with an increase of the intra-alveolar pressure. This problem is particularly relevant for prolonged use of mechanical chest compressions. In clinical practice, this problem can result in haemoptysis. The solutions used by different teams are very variable. (i) Mechanical ventilation (with the increase of pressure alarm to its maximum): this technique has the advantage to free hands and to control the rate and volume of gas delivered; however, it can be barotraumatic. (ii) Bag ventilation at the rate of 10 breaths delivered per minute: this technique can be harmful by an accidental hyperventilation rate and has little control over the volume of gas delivered, but it is probably less traumatic. (iii) '30/2' CPR alternating 30 compressions with 2 bag ventilations, knowing that the interruption of cardiac compressions has harmful haemodynamic effects.
The other questions are: which control group is relevant for clinical practice? CPR using mechanical chest compressions was compared with optimized manual CPR, but what are the results in comparison with standard CPR? We could also compare mechanical CPR with CPR using active compression/decompression associated with an impedance threshold device (ITD) valve or mechanical chest compression with an ITD valve. 10 However, we must keep in mind why we use mechanical chest compressions. We used this therapy for patients with prolonged cardiac arrest. We know with high levels of evidence that the quality of the CPR is highly associated with survival. This quality depends on the association of good compression depth, good fraction active compression time, and good chest recoil. 11 The potential complications of mechanical chest compressions are to be balanced with a low quality prolonged CPR, safety of the EMS personnel (they can be seated during transportation of the patient), a better organization of care (hands free CPR), etc. The use of mechanical chest compressions should definitely be considered in the care package of cardiac arrest. We must learn to look at the Force beyond the Dark side of the mechanical cardiac massage (Figure 1) .
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